IDH1 and glioma: Finally, the evidence that gliomas harboring IDH1 R132H mutation carry an immunogenic epitope that can induce a CD4+ T-helper/T-cell response able to hamper tumor growth through the production of pro-inflammatory cytokines such as interferon-γ and TNF-α, lead to the development of vaccines against IDH1 mutant epitopes.